Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Barbara Burtness MD
Barbara Burtness MD Advisory Board
David Henry MD
David Henry MD Advisory Board
Roger Stupp MD
Roger Stupp MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · January 21, 2016

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated FOLFOX ± Cetuximab

JAMA Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

JAMA Oncology
Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage 3 Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial
JAMA Oncol 2016 Jan 14;[EPub Ahead of Print], J Taieb, A Zaanan, K Le Malicot, C Julié, H Blons, L Mineur, J Bennouna, J Tabernero, E Mini, G Folprecht, JL Van Laethem, C Lepage, JF Emile, P Laurent-Puig

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated